Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001193125-21-213350
Filing Date
2021-07-13
Accepted
2021-07-12 21:08:28
Documents
1
Group Members
FRANK M. SANDSSANDS CAPITAL GLOBAL VENTURE FUND II, L.P.SANDS CAPITAL LIFE SCIENCES PULSE FUND, LLC

Document Format Files

Seq Description Document Type Size
1 SC 13G d165446dsc13g.htm SC 13G 83523
  Complete submission text file 0001193125-21-213350.txt   85237
Mailing Address 4435 NORTH FIRST STREET, SUITE 360 LIVERMORE CA 94551
Business Address 4435 NORTH FIRST STREET, SUITE 360 LIVERMORE CA 94551 925-368-8508
Acumen Pharmaceuticals, Inc. (Subject) CIK: 0001576885 (see all company filings)

EIN.: 364108129 | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-92677 | Film No.: 211086644
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O SANDS CAPITAL VENTURES, LLC 1000 WILSON BOULEVARD, SUITE 3000 ARLINGTON VA 22209
Business Address C/O SANDS CAPITAL VENTURES, LLC 1000 WILSON BOULEVARD, SUITE 3000 ARLINGTON VA 22209 703-562-4000
Sands Capital Ventures Discovery Fund III, L.P. (Filed by) CIK: 0001870491 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE
Type: SC 13G